Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with abdominal nodal disease had inferior lymphoma specific survival (p=0.04) and presented with higher age adjusted IPI (p<0.001), lactate dehydrogenase (p<0.001) and more often advanced stage (p<0.001), bulky disease (p<0.001), B-symptoms (p<0.001), and double expression of MYC and BCL2 (p=0.02) compared to patients without nodal abdominal involvement, but less often extranodal involvement (p<0.02).
|
31785002 |
2020 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma.
|
31142587 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lastly, high-intensity chemotherapy (either dose-adjusted rituximab and etoposide-prednisone-vincristine-cyclophosphamide-doxorubicin or rituximab and hyperfractionated cyclophosphamide-vincristine-doxorubicin-dexamethasone treatment) did not improve survival in patients with MYC-EC and MYC-rearranged lymphoma when compared with rituximab-cyclophosphamide-hydroxydaunomycin-vincristine-prednisone therapy.
|
30496802 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of SMYD2 was validated in vivo but the functional analysis was constrained by in vitro loss of p53 in RUNX2/MYC lymphoma cell lines.
|
31257681 |
2019 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, APE1 is unexpectedly dispensable for SHM in the S region and translocation between immunoglobulin heavy chain (IgH) and c-myc genes in the mouse B lymphoma cell line, CH12F3-2A.
|
30877298 |
2019 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Double-hit lymphoma (DHL) is defined as lymphoma with concurrent BCL2 and MYC translocations.
|
29310838 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of one allele of KAT6A extends the median survival of mice with MYC-induced lymphoma from 105 to 413 days<sup>11</sup>.
|
30069049 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphatidylinositol 3 kinase (PI3K)-glycogen synthase kinase β (GSK3β) axis plays a central role in MYC-driven lymphomagenesis, and MYC targeting with bromodomain and extraterminal protein family inhibitors (BETi) is a promising treatment strategy in lymphoma.
|
30134175 |
2018 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The latest revision of lymphoma's World Health Organization classification describes the new provisional entity "Burkitt-like lymphoma with 11q aberration" (BLL, 11q) as lacking MYC rearrangement, but harboring the specific11q-gain/loss aberration.
|
29272887 |
2017 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Dual-expressor lymphoma is a form of DLBCL with overexpression of MYC and BCL2/BCL6.
|
28952038 |
2017 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There were 47 DTHLs, 36 cases with MYC and BCL2 and/or BCL6 extra signals (ES) and/or rearrangements (ES group, excludes DTHLs), 9 with MYC rearrangements only (single-hit lymphoma), and 95 with no MYC abnormalities (NM).
|
28614202 |
2017 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
|
27717585 |
2017 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In B-lymphoma cells, as a consequence of PCYT1A upregulation, MYC impeded lymphoma cells undergo a mitophagy-dependent necroptosis.
|
28686226 |
2017 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Real-time polymerase chain reaction showed C-MYC mRNA expression in lymphoma-type and acute-type samples were significantly higher than in smoldering-type (P<0.01).
|
28498285 |
2017 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty-four MYC-R lymphoma cases were studied: 21 treated with R-CHOP and 13 treated with BURKIMAB.
|
28648593 |
2017 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In total, 76 patients with diffuse large B-cell lymphoma had MYC extra copies including 43 cases of double or triple extra copy lymphoma; 105 patients had diffuse large B-cell lymphoma with MYC-R including 56 double- or triple-hit lymphoma; and 482 diffuse large B-cell lymphoma patients had no MYC abnormality (MYC normal).
|
28776574 |
2017 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate that coordinated targeting of rDNA transcription and PI3K-AKT-mTORC1-dependent ribosome biogenesis and protein synthesis provides a remarkable improvement in survival in MYC-driven B lymphoma.
|
26490423 |
2016 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC translocations occurred as single hit (only MYC rearranged, 63%) or multiple hit lymphoma (37%) and presented as acute leukemia (AL) (14%), Burkitt lymphoma (30%), chronic lymphocytic leukemia (CLL) (21%) or other mature B-cell neoplasms (35%).
|
27810071 |
2016 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In our patient series, we confirm the dismal prognosis of MYC+ lymphoma patients.
|
26820684 |
2016 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Most of the refractory patients exhibit double-hit lymphoma (MYC-BCL2 rearrangement) or double-protein-expression lymphoma (MYC-BCL2 hyperexpression) which have a more aggressive clinical picture.
|
27913503 |
2016 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we report that the Zn(2+)-finger transcription factor ASCIZ (ATMIN, ZNF822) synergizes with MYC to activate the expression of dynein light chain (DYNLL1, LC8) in the murine Eμ-Myc model of lymphoma.
|
26832406 |
2016 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, Burkitt leukemia/lymphoma is a mature B lymphocyte neoplasm with a characteristic germinal center immunophenotype and MYC rearrangement.
|
26489677 |
2015 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogene MYC is deregulated in many human cancers, especially in lymphoma.
|
25692307 |
2015 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identify lymphoma subtype-specific enhancers in the MYC locus that are silenced in lymphomas with MYC-activating rearrangements and are associated with germline polymorphisms that alter lymphoma risk.
|
26229090 |
2015 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MYC upregulation simultaneously sensitizes cells to apoptosis and activated lymphocytes and lymphoma cells have pro-survival attributes that allow MYC-driven proliferation to prevail.
|
24731854 |
2015 |